User login
Key clinical point: Lorlatinib extends progression-free survival (PFS) and reduces central nervous system (CNS) progression compared with crizotinib in patients with anaplastic lymphoma kinase positive (ALK+) advanced nonsmall cell lung cancer (NSCLC) and with or without brain metastases at baseline.
Major finding: In patients with and without baseline brain metastasis, lorlatinib vs. crizotinib improved the 12-month PFS (78% vs. 22% and 78% vs. 45%, respectively) and 12-month cumulative incidence of CNS progression (7% vs. 72% and 1% vs. 18%, respectively).
Study details: The data come from a post hoc analysis of the CROWN trial including patients with ALK+ NSCLC and with (n = 78) or without (n = 218) brain metastasis at baseline.
Disclosures: The CROWN trial was funded by Pfizer. Many authors reported ties with multiple pharmaceutical companies, including Pfizer.
Source: Solomon BJ et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non–small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022 (May 23). Doi: 10.1200/JCO.21.02278
Key clinical point: Lorlatinib extends progression-free survival (PFS) and reduces central nervous system (CNS) progression compared with crizotinib in patients with anaplastic lymphoma kinase positive (ALK+) advanced nonsmall cell lung cancer (NSCLC) and with or without brain metastases at baseline.
Major finding: In patients with and without baseline brain metastasis, lorlatinib vs. crizotinib improved the 12-month PFS (78% vs. 22% and 78% vs. 45%, respectively) and 12-month cumulative incidence of CNS progression (7% vs. 72% and 1% vs. 18%, respectively).
Study details: The data come from a post hoc analysis of the CROWN trial including patients with ALK+ NSCLC and with (n = 78) or without (n = 218) brain metastasis at baseline.
Disclosures: The CROWN trial was funded by Pfizer. Many authors reported ties with multiple pharmaceutical companies, including Pfizer.
Source: Solomon BJ et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non–small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022 (May 23). Doi: 10.1200/JCO.21.02278
Key clinical point: Lorlatinib extends progression-free survival (PFS) and reduces central nervous system (CNS) progression compared with crizotinib in patients with anaplastic lymphoma kinase positive (ALK+) advanced nonsmall cell lung cancer (NSCLC) and with or without brain metastases at baseline.
Major finding: In patients with and without baseline brain metastasis, lorlatinib vs. crizotinib improved the 12-month PFS (78% vs. 22% and 78% vs. 45%, respectively) and 12-month cumulative incidence of CNS progression (7% vs. 72% and 1% vs. 18%, respectively).
Study details: The data come from a post hoc analysis of the CROWN trial including patients with ALK+ NSCLC and with (n = 78) or without (n = 218) brain metastasis at baseline.
Disclosures: The CROWN trial was funded by Pfizer. Many authors reported ties with multiple pharmaceutical companies, including Pfizer.
Source: Solomon BJ et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non–small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022 (May 23). Doi: 10.1200/JCO.21.02278